Received: 6.24.2010
First Name: Jennifer
Last Name: Levine
Institution: Columbia University Medical Center
Address 1: 161 Fort Washington Ave, IP-7
Address 2:
City: New York
State/Province: NY
Country: USA
Zip: 10032
Phone: 212-305-2368
Alternate Phone: 917-608-7467
Email: jl175@columbia.edu

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes
The specific aims are clear and focused.: Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

---

Project Title: Premature Menopause in Survivors of Childhood Cancer
Planned research population (eligibility criteria): Patients Eligibility: 1) Female older than age 18 years at time of 2007 follow-up questionnaire. 2) completed 2007 follow-up questionnaire Exclusion criteria: 1) other diagosis associated with ovarian dysfunction (e.g. Turner's syndrome) 2) had spontaneous menses or ceased spontaneous menstruation within the first five years following cancer diagnosis 3) received more than 30 Gy of RT to the brain and/or had a primary tumor in the region of the hypothalmus-pituitary gland 4) questionnaire completed by someone other than the participant 5) developed a second malignancy before the onset of menopause 6)incomplete or unavailable RT data Sibling controls 1) females older than age 18 2) acheived spontaneous menarche
Proposed specific aims: 1. Compare the incidence of premature menopause in the patient population compared to sibling controls. 2) Compare the incidence of premature menopause identified in the 2007 survey to the incidence from the 2000 survey. 3) Identify treatment, disease and demographic characteristics that predict risk of premature menopause.
Will the project require non-CCSS funding to complete?: No
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: No
Biological Samples: No
Medical record data: No
If yes to any of the above, please briefly describe.:

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy:
Chronic Disease: Primary
Psychology / Neuropsychology:
Genetics:
Cancer Control:
Epidemiology / Biostatistics: Secondary

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

Late mortality:
Second Malignancy:

Health Behaviors

Tobacco:
Alcohol:
Physical activity:
Medical screening:
Other:
If other, please specify:

Psychosocial

Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

Medical conditions

Hearing/Vision/Speech:
Hormonal systems: Primary
Heart and vascular:
Respiratory:
Digestive:

Surgical procedures: Correlative Factors
Brain and nervous system:
Other:
If other, please specify:

Medications

Describe medications:

Pregnancy and offspring: Correlative Factors
Family History:

Psychologic/Quality of Life

BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

Chronic conditions (CTCAE v3):
Health status:

Demographic

Age: Correlative Factors
Race: Correlative Factors
Sex:
Others:
If others, please specify:

Cancer treatment

Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery: Correlative Factors

Anticipated sources of statistical support

CCSS Statistical Center: Yes
Local institutional statistician:
If local, please provide the name(s) and contact information of the statistician(s) to be involved.:
Will this project utilize CCSS biologic samples?: No

If yes, which of the following?

Buccal cell DNA:
Peripheral blood:
Lymphoblastoid cell lines:
Second malignancy pathology samples:
Other requiring collection of samples:
If other, please explain:

Other general comments: